Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

61.10 -1.16 (-1.86%)

Streaming Delayed Price Updated: 2:57 PM EDT, May 26, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	187,185
Open	62.44
Bid (Size)	61.01 (200)
Ask (Size)	61.20 (100)
Prev. Close	62.26
Today's Range	60.98 - 62.89
52wk Range	38.51 - 85.25
Shares Outstanding	42,600,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Performance

YTD	-24.3%	-24.3%
1 Month	+0.3%	+0.3%
3 Month	-12.2%	-12.2%
6 Month	-25.6%	-25.6%
1 Year	+45.9%	+45.9%

More News

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

May 14, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗

May 06, 2026

Via Chartmill

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗

March 02, 2026

Via Chartmill

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗

February 23, 2026

Via Chartmill

Tarsus to Participate in Upcoming Investor Conferences

May 07, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus (TARS) Q1 2026 Earnings Transcript ↗

May 06, 2026

Via The Motley Fool

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

May 06, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 29, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Combines High-Growth Momentum with a Favorable Technical Setup ↗

January 01, 2026

Via Chartmill

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

March 31, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗

March 24, 2026

Via The Motley Fool

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

March 23, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Via The Motley Fool

Tarsus to Participate in Upcoming Investor Conferences

February 26, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus (TARS) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

What's going on in today's after hours session ↗

February 23, 2026

Via Chartmill

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

February 23, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

February 18, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

February 17, 2026

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout ↗

December 10, 2025

Via Chartmill

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

Via The Motley Fool

Tarsus to Participate in Upcoming Investor Conference

November 24, 2025

From Tarsus Pharmaceuticals, Inc

Via GlobeNewswire

TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum ↗

November 22, 2025

Via Chartmill

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?

Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market

What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?

The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 61.10

When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 05/26/26 02:57 PM ET

What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.60B

How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?

Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.